Drug Profile
RGX 111
Alternative Names: RGX-111Latest Information Update: 13 Nov 2023
Price :
$50
*
At a glance
- Originator REGENXBIO
- Class Gene therapies
- Mechanism of Action Gene transference; Iduronidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Mucopolysaccharidosis I
Most Recent Events
- 13 Nov 2023 RGX 111 is available for licensing as of 09 Nov 2023. https://www.regenxbio.com/therapeutic-programs/
- 24 Feb 2023 Updated efficacy, safety and pharmacodynamic data from a phase I/II trial in Mucopolysaccharidosis I released by REGENXBIO and presented at the 19th Annual WORLDSymposium
- 31 Dec 2022 RGX 111 receives advanced therapy medicinal products (ATMP) classification from the EMA, prior to December 2022